<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00652912</url>
  </required_header>
  <id_info>
    <org_study_id>B043204</org_study_id>
    <nct_id>NCT00652912</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Clonazepam ODT Under Fasting Conditions</brief_title>
  <official_title>Comparative, Randomized, Single-Dose, Bioavailability Study of Kali's Clonazepam ODT 1 mg With That of Klonopin Wafers 1 mg ODT in Healthy Adult Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cetero Research, San Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the single-dose bioavailability of Clonazepam ODT 1 mg and Klonopin Wafers 1 mg&#xD;
      ODT&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the single -dose bioavailability of kali's Clonazepam ODT 1 mg with that of&#xD;
      Klonopin Wafers 1 mg ODT by Roche pharmaceuticals following a single oral dose under fasting&#xD;
      conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">May 2004</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extent of Absorption</measure>
    <time_frame>24 Hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>To Determine Bioequivalence Under Fasting Conditions</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received the Kali formulated products under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received the Roche's product under fasting conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonazepam</intervention_name>
    <description>ODT, 1 mg</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Klonopin Wafers</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Klonopin Wafers</intervention_name>
    <description>ODT, 1 mg</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Clonazepam ODT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subjects selected for this study will be alt least 18 years of age.Females must be&#xD;
             of non- childbearing potential (postmenopausal for alt least 6 months or surgically&#xD;
             sterile)&#xD;
&#xD;
          -  Each subject shall be given a general physical examination within 28 days of the&#xD;
             study. Such examination includes, but is not limited to, blood pressure, general&#xD;
             observations, and history.&#xD;
&#xD;
          -  Each female subject will be given a serum pregnancy test as part of the pre-study&#xD;
             process.&#xD;
&#xD;
          -  At the end of the study, the subjects will have an exit evaluation consisting of&#xD;
             interim history, global evaluation, and clinical laboratory measurements.&#xD;
&#xD;
          -  Adequate blood and urine samples should be obtained within 28 days before beginning of&#xD;
             the first period and at the end of the trail for clinical laboratory.&#xD;
&#xD;
          -  Clinical laboratory measurements will include the following:&#xD;
&#xD;
          -  Hematology: hemoglobin, hematocrit, red blood cell count (with differential)&#xD;
&#xD;
          -  Clinical Chemistry: creatinine, BUN, glucose, SGOT/ AST, SGPT/ALT, bilirubin, and&#xD;
             alkaline phosphate.&#xD;
&#xD;
          -  Urine Analysis: pH, specific gravity, protein, glucose, ketones, bilirubin, occult&#xD;
             blood and cells.&#xD;
&#xD;
          -  HIV Screen: (Pre-study only)&#xD;
&#xD;
          -  Hepatitis-B, C Screen: (Pre-study only)&#xD;
&#xD;
          -  Drugs of Abuse Screen: (Pre-study at check -in each dosing period)&#xD;
&#xD;
          -  Electrocardiograms of all participating subjects will be recorded before initiation of&#xD;
             the study and filed with each subject's case report forms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a history of chronic alcohol consumption (during past 2 years), drug&#xD;
             addiction, or serious gastrointestinal, renal, hepatic or cardiovascular disease,&#xD;
             tuberculosis epilepsy, asthma, (during pat 5 years), diabetes, psychosis or glaucoma&#xD;
             will not be eligible for this study.&#xD;
&#xD;
          -  Subjects whose clinical laboratory test values are outside the normal range may be&#xD;
             retested at the discretion of the clinical investigator. If the clinical values are&#xD;
             outside the range on retesting, the subject will not be eligible to participate in the&#xD;
             study unless the clinical investigator deems the result to not be significant.&#xD;
&#xD;
          -  Subjects who have a history of allergic response to the class of drug being tested&#xD;
             should excluded form the study.&#xD;
&#xD;
          -  All subjects will have urine samples assayed for the presence of drugs of abuse as&#xD;
             part of the clinical laboratory screening procedures and check in each dosing period.&#xD;
             Subjects found to have urine concentration of any of the tested drugs will not be&#xD;
             allowed to participate.&#xD;
&#xD;
          -  Subjects should not have donated blood and/plasma for at least thirty (30) days prior&#xD;
             to the first dosing of the study&#xD;
&#xD;
          -  Subjects who have taken any investigational drug within thirty (30) days prior to the&#xD;
             first dosing of the study will not be allowed to participate.&#xD;
&#xD;
          -  Female subjects with childbearing potential will not be allowed to participate.&#xD;
&#xD;
          -  All female subjects will be screened for pregnancy at check in each study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Ziaee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cetero Research, San Antonio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary Shillito</last_name>
    <role>Study Director</role>
    <affiliation>Cetero Research, San Antonio</affiliation>
  </overall_official>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2008</study_first_posted>
  <last_update_submitted>April 3, 2008</last_update_submitted>
  <last_update_submitted_qc>April 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Alfred Elvin/ Director Biopharmaceutics</name_title>
    <organization>Par Pharmaceutical, Inc.</organization>
  </responsible_party>
  <keyword>bioequivalence, Clonazepam ODT , fasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

